About Free fatty acid receptor 1
Free fatty acid receptor 1 (FFAR1) is a protein
from Homo sapiens identified by UniProt accession
O14842, 300 residues long.
MolForge cross-references it against 0 known binders and
177 disease associations.
Target properties
| Protein name | Free fatty acid receptor 1 |
|---|
| UniProt accession | O14842 |
|---|
| Gene | FFAR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 300 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (7)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (177)
Diseases linked to this target (Open Targets).
- diabetes mellitus · score 0.37
- type 2 diabetes mellitus · score 0.33
- endometrial cancer · score 0.25
- glioblastoma multiforme · score 0.25
- Parkinson disease · score 0.24
- Alzheimer disease · score 0.24
- multiple sclerosis · score 0.24
- lysosomal storage disease · score 0.24
- neurodegenerative disease · score 0.24
- breast adenocarcinoma · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O14842-F1 | alphafold | PREDICTED | 89.77 | — |
Amino-acid sequence (300 residues)
MDLPPQLSFG LYVAAFALGF PLNVLAIRGA TAHARLRLTP SLVYALNLGC SDLLLTVSLP LKAVEALASG AWPLPASLCP VFAVAHFFPL YAGGGFLAAL SAGRYLGAAF PLGYQAFRRP CYSWGVCAAI WALVLCHLGL VFGLEAPGGW LDHSNTSLGI NTPVNGSPVC LEAWDPASAG PARFSLSLLL FFLPLAITAF CYVGCLRALA RSGLTHRRKL RAAWVAGGAL LTLLLCVGPY NASNVASFLY PNLGGSWRKL GLITGAWSVV LNPLVTGYLG RGPGLKTVCA ARTQGGKSQK
Explore Free fatty acid receptor 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets